Evidence map›Paper›PMID 40255441›Full record

ArticleJCEM case reports2025

Successful Volume Control of Invasive Pituitary Adenoma Tumor With Pasireotide: A New Horizon for a Challenging Disease.

Tarik Elhadd, Shahd I Ibrahim, Elabbass Abdelmahmuod, Susan M Webb

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tarik ElhaddPituitary Clinic, Endocrine Section, Department of Medicine, Hamad General Hospital, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar.ORCID https://orcid.org/0000-0003-3451-503X
Shahd I IbrahimPituitary Clinic, Endocrine Section, Department of Medicine, Hamad General Hospital, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar.
Elabbass AbdelmahmuodPituitary Clinic, Endocrine Section, Department of Medicine, Hamad General Hospital, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar.
Susan M WebbDepartment of Medicine, Univ Autonoma Barcelona, Research Center for Pituitary Diseases, Institut de Recerca Sant Pau (IIB-Sant Pau) and CIBERER Unit 747, ISCIII, Department of Endocrinology, Hospital S Pau, Barcelona 08025, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 62-year-old Sudanese female was diagnosed with a nonfunctioning pituitary adenoma in 2006. Despite undergoing 3 transsphenoidal surgeries and radiotherapy, her tumor persisted, causing debilitating symptoms, including headaches and visual defects. As a last resort, she was treated with pasireotide, a second-generation somatostatin analog with a broader receptor affinity than first-generation drugs. Over 6 months, the tumor mass was stabilized, and her symptoms, including headaches, disappeared. This case demonstrates a potential new therapeutic possibility for treating resistant pituitary adenoma with pasireotide, offering hope for patients when traditional treatments fail.

Indexed as

nonfunctioning pituitary tumorpasireotidepituitary tumorresistant invasive pituitary adenoma

Identifiers

PMID40255441
PMCPMC12007491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.